The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Bacteriophages that comprise a tail fiber protein sequence comprising a C terminus host recognition site described by SEQ ID NO: 1 and which infect Ralstonia solanacearum which causes bacterial wilt disease are disclosed. Compositions comprising these bacteriophages may be employed as wilt control agents. Methods for preventing or treating diseases caused by Ralstonia solanacearum such as bacterial wilt disease are also disclosed. A bacterial wilt disease control method in a plant may include administering such bacteriophages to a plant or to a plant growth medium and can be effective against a wide variety of Ralstonia solanacearum strains. Nucleic acids encoding the C terminus host recognition site and amino acid sequences comprising the host recognition site are also disclosed.

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.

Bacteriophages that comprise a tail fiber protein sequence comprising a C terminus host recognition site described by SEQ ID NO: 1 and which infect Ralstonia solanacearum which causes bacterial wilt disease are disclosed. Compositions comprising these bacteriophages may be employed as wilt control agents. Methods for preventing or treating diseases caused by Ralstonia solanacearum such as bacterial wilt disease are also disclosed. A bacterial wilt disease control method in a plant may include administering such bacteriophages to a plant or to a plant growth medium and can be effective against a wide variety of Ralstonia solanacearum strains. Nucleic acids encoding the C terminus host recognition site and amino acid sequences comprising the host recognition site are also disclosed.